Key result
Silencing LncRNA-MALAT 1 significantly reduced cardiomyocyte pyroptosis and improved cardiac function and morphology in diabetic models by targeting NLRP3 expression.
Why the study?
The mechanism of long non-coding RNA regulation of cellular scorching (pyroptosis) in diabetic cardiomyopathy remains unclear.
Silencing LncRNA-MALAT 1 attenuates cardiomyocyte pyroptosis and improves cardiac function in diabetic cardiomyopathy models by targeting the NLRP3 pathway.
Answers are grounded in this paper and cite their sources.
Should not yet change DCM practice; hypothesis-generating for MALAT1 in cardiomyocyte scorching and requires prospective validation.
Diabetic cardiomyopathy (DCM) is a common complication of diabetes mellitus, often leading to heart failure, arrhythmias and sudden death. Long-stranded non-coding RNA (LncRNA), an endogenous non-coding long-stranded RNA, is associated with diabetic cardiomyopathy. However, the mechanism of LncRNA regulation of cellular scorching in diabetic cardiomyopathy remains unclear. This study aimed to elucidate whether MALAT 1 affects cardiomyocyte scorching in DCM patients. METHODS: Streptozotocin (STZ) at 35 mg/Kg was used to induce diabetes in rats. H9C2 cardiomyocytes and primary cardiomyocytes (PCM) were cultured at 5.5 and 50 mmol/L glucose, respectively. The expression levels of MALAT 1 and scorch death-related genes were detected by RT-PCR using plasmids to suppress or overexpress the related genes, respectively. Immunofluorescence, RT-PCR and Western blot were used to detect the extent of cell scorch death. RESULTS: MALAT 1 expression was elevated in diabetic and high glucose-induced cardiomyocytes and myocardial tissue from diabetic mice (p<0.001). Silencing of MALAT 1 alleviated cardiomyocyte scorch death by targeting NLRP3. Furthermore, silencing MALAT 1 reduced cell death and improved cardiac function and morphology. CONCLUSIONS: MALAT 1 is overexpressed in DCM and silencing MALAT 1 inhibits cell scorch death by affecting NLRP3 expression. We clarify for the first time that MALAT 1 may be a new therapeutic target for DCM.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2022) studied Diabetic cardiomyopathy (n=40). MALAT 1 silencing (shRNA/siRNA) vs. Diabetic/high-glucose control was evaluated on MALAT 1 expression and cardiomyocyte pyroptosis (p=<0.001). Silencing LncRNA-MALAT 1 significantly reduced cardiomyocyte pyroptosis and improved cardiac function and morphology in diabetic models by targeting NLRP3 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: